CD274 and small cell lung carcinoma: To our knowledge, only three studies have evaluated the cost-effectiveness of combination chemotherapy with PD-L1 inhibitors as a first-line regimen for ES-SCLC from the perspective of the Chinese health system (Li et al., 2019; Liu and Kang, 2022; Tong et al., 2022).